BOPA survey on monitoring and treatments for immune related myocarditis

The BOPA Immunotherapy Specialist Interest Group invites healthcare professionals to collaborate with us by completing this survey relating to access to drugs for IR-myocarditis.

This builds on our previous work exploring the known disparity across the UK with regards to access to drugs for immune-related (IR) adverse effects. IR-myocarditis is a rare and serious complication of immune checkpoint inhibitors (ICI).

Firstly, we aim to understand what cardiac assessments are undertaken prior to ICI therapy and the monitoring during therapy. Also, we are wanting to discover which drugs and in particular which steroid sparing agents are prescribed for IR-myocarditis.

Please find below the link to the survey, which should take around 12 minutes to complete. Analysis of these results will be used to highlight the difficulties in treating patients with this life-threatening IR adverse effect.

Please fill out the survery here!